Skip to NavigationSkip to content

horizon

Horizon and Fulcrum Therapeutics form CRISPR collaboration

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform to identify novel targets for regulating gene expression in genetic diseases for which no effective treatments currently exist.

Fulcrum are a US-based firm founded as recently as July 2016 and have chosen Horizon as their preferred CRISPR-based screening platform provider to work on their projects going forward. The partnership is expected to run for between five and seven months.

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is marketed under the trade names Imukin, Imukine, Immukin and Immukine in an estimated 30 countries across Europe and the Middle East.

This drug is intended for patients in a variety of different genetic illnesses, including severe, malignant osteoporosis and chronic granulmatous disease. Horizon already licenses interferon gamme-1b as Actimmune in the US, Canada and Japan.

Depomed criticised by investors and urged to explore potential sale

Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called on the board to explore a potential sale of the company.

Horizon receives European go-ahead for Ravicti

EU flags

The European Commission has approved Ravicti for rare urea cycle disorders. 

Ravicti, (glycerol phenylbutyrate), is an oral liquid developed by Horizon Pharma an adjunctive therapy for the chronic management of adults and children two months of age and older with six subtypes of urea cycle disorders (UCDs). 

Takeover hostilities resume between Depomed and Horizon

Nucynta (tapentadol)
Depomed says Horizon's bid is based on illegal use of information about Nucynta

The bitter takeover row between Horizon and Depomed has escalated after Depomed dismissed its suitor’s latest advances, and warned it was willing to go through ‘protracted litigation and a proxy fight’.

In a public letter to Horizon Pharma, Depomed dismissed the latest move in the Dublin-based company’s strategy, saying “it does not make any sense to engage unless you [Horizon] make a sufficiently compelling and detailed proposal.”

Depomed rejects Horizon’s latest takeover bid

Depomed has rejected Horizon Pharma’s latest bid, stating the proposal is ‘inadequate’ and ’undervalues’ the company.

The Irish pharma company offered a $33 per share proposal, up from its previous $29.25 per share offer valued at approximately $2.0 billion.

Horizon attempts a hostile $3bn Depomed takeover

Deopmed logo
Depomed has rejected unsolicited bids for its shares from Horizon

Dublin-based specialty pharmaceutical company Horizon has launched a bid to buy Depomed for $3 billion.

Horizon, a biopharma company focussed on producing drug treatments for arthritis and other inflammatory diseases, say they have made repeated attempts for deal discussions with Depomed, which makes pain treatments and products treating conditions related to the nervous system.

AZ and Horizon in cancer tie-up

Astrazeneca image

 

AstraZeneca has signed a deal with British biotech firm Horizon Discovery to look at a number of genotypes to see whether they might be useful in developing cancer treatments.

The companies are tight-lipped about money, with no word on how much Horizon is receiving up front - although the firm could receive as much as $88 million in milestones, assuming various targets (which are again undisclosed) are met.

AstraZeneca sells arthritis drug for $35 million

Vimovo image

AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million. 

AZ retains the rights to Vimovo (naproxen/esomeprazole magnesium) outside the US and the contract sees Horizon paying $35 million upfront for the drug - followed by a 10% royalty on its net sales to pharma firm Pozen, who licensed it to AZ in 2010. 

But Horizon says they are guaranteed a minimum of $5 million in royalty payments in 2014 from Vimovo, and $7.5 million for each year after that providing generic competition does not elbow in.

Horizon Discovery chairman steps down from Board

Published on: 24/10/13

Research tools firm Horizon Discovery has confirmed that David Evans has stepped down as chairman of its Board.

Dr Ian Gilham, who was recently appointed as a non-executive director for the company, will act as its interim chairman. Horizon is currently seeking a non-executive with international standing to act as chairman, who will work closely with the Board of directors and chief executive.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches